CoChat
Sign Up
Cited by 233Maternal and fetal healthcarePregnancy and preeclampsia studiesReproductive System and Pregnancy

Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomarkers

Open access
Bartels, Helena C., Postle, James D., Downey, Paul, Brennan, Donal J.·2018·Disease Markers
DOI 10.1155/2018/1507674PMC PMC6051104
Open this paper in CoChat — free accountOpen PDF

Abstract

Background . Placenta accreta spectrum (PAS) is a condition of abnormal placental invasion encompassing placenta accreta, increta, and percreta and is a major cause of severe maternal morbidity and mortality. The diagnosis of a PAS is made on the basis of histopathologic examination and characterised by an absence of decidua and chorionic villi are seen to directly adjacent to myometrial fibres. The underlying molecular biology of PAS is a complex process that requires further research; for ease, we have divided these processes into angiogenesis, proliferation, and inflammation/invasion. A number of diagnostic serum biomarkers have been investigated in PAS, including human chorionic gonadotropin (HCG), pregnancy-associated plasma protein-A (PAPP-A), and alpha-fetoprotein (AFP). They have shown variable reliability and variability of measurement depending on gestational age at sampling. At present, a sensitive serum biomarker for invasive placentation remains elusive. In summary, there are a limited number of studies that have contributed to our understanding of the molecular biology of PAS, and additional biomarkers are needed to aid diagnosis and disease stratification.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2018/1507674

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 95

  1. [1]Irving C. Hertig A. T. A study of placenta accreta Surgery, Gynecology & Obstetrics 1937 38 6 1088 1200 10.1016/S0002-9378(39)90680-0 · DOI
  2. [2]Jauniaux E. Chantraine F. Silver R. M. Langhoff-Roos J. and for the FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel FIGO consensus guidelines on placenta accreta spectrum disorders: epidemiology International Journal of Gynecology & Obstetrics 2018 140 3 265 273 10.1002/ijgo.12407 2-s2.0-85041710745 29405321 · DOI · Paper page
  3. [3]Chuong E. Evolutionary perspectives into placental biology and disease Applied & Translational Genomics 2013 2 64 69 10.1016/j.atg.2013.07.001 2-s2.0-84890158743 27896057 PMC5121266 · DOI
  4. [5]Silver R. M. Barbour K. D. Placenta accreta spectrum: accreta, increta, and percreta Obstetrics and Gynecology Clinics of North America 2015 42 2 381 402 10.1016/j.ogc.2015.01.014 2-s2.0-84931402098 26002174 · DOI
  5. [6]O’Brien J. M. Barton J. R. Donaldson E. S. The management of placenta percreta: conservative and operative strategies American Journal of Obstetrics & Gynecology 1996 175 6 1632 1638 10.1016/S0002-9378(96)70117-5 2-s2.0-0030460544 8987952 · DOI · Paper page
  6. [7]Knight M. Nair M. Tuffnell D. Saving Lives, Improving Mothers’ Care - Lessons Learned to Inform Maternity Care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2013–15 2017 Oxford National Perinatal Epidemiology Unit, University of Oxford
  7. [9]Bailit J. L. Grobman W. A. Rice M. M. Morbidly adherent placenta treatments and outcomes Obstetrics & Gynecology 2015 125 3 683 689 10.1097/AOG.0000000000000680 2-s2.0-84923565006 25730233 PMC4347990 · DOI · Paper page
  8. [11]Jauniaux E. Bhide A. Burton G. J. Chapter 2 Pathophysiology of accreta Placenta Accreta Syndrome, Silver 2017 Taylor and Francis https://www.crcpress.com/Placenta-Accreta-Syndrome/Silver/p/book/9781498745963
  9. [12]Parra-Herran C. Djordjevic B. Histopathology of placenta creta: chorionic villi intrusion into myometrial vascular spaces and extravillous trophoblast proliferation are frequent and specific findings with implications for diagnosis and pathogenesis International Journal of Gynecological Pathology 2016 35 6 497 508 26630223
  10. [13]Dannheim K. Shainker S. A. Hecht J. L. Hysterectomy for placenta accreta; methods for gross and microscopic pathology examination Archives of Gynecology and Obstetrics 2016 293 5 951 958 10.1007/s00404-015-4006-5 2-s2.0-84954327404 26758078 · DOI
  11. [14]Miller E. S. Linn R. L. Ernst L. M. Does the presence of placental basal plate myometrial fibres increase the risk of subsequent morbidly adherent placenta: a case–control study BJOG: An International Journal of Obstetrics & Gynaecology 2016 123 13 2140 2145 10.1111/1471-0528.13579 2-s2.0-85028267535 26265563 · DOI
  12. [15]Jauniaux E. Collins S. Burton G. J. Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging American Journal of Obstetrics & Gynecology 2018 218 1 75 87 10.1016/j.ajog.2017.05.067 2-s2.0-85024905432 28599899 · DOI · Paper page
  13. [16]Ernst L. M. Linn R. L. Minturn L. Miller E. S. Placental pathologic associations with morbidly adherent placenta: potential insights into pathogenesis Pediatric and Developmental Pathology 2017 20 5 387 393 10.1177/1093526617698600 2-s2.0-85032007597 28812469 · DOI
  14. [17]Tantbirojn P. Crum C. P. Parast M. M. Pathophysiology of placenta creta: the role of decidua and extravillous trophoblast Placenta 2008 29 7 639 645 10.1016/j.placenta.2008.04.008 2-s2.0-46549084302 18514815 · DOI
  15. [18]Hanahan D. Weinberg R. A. Hallmarks of cancer: the next generation Cell 2011 144 5 646 674 10.1016/j.cell.2011.02.013 2-s2.0-79952284127 21376230 · DOI · Paper page
  16. [19]Tseng J. Chou M. Differential expression of growth-, angiogenesis- and invasion-related factors in the development of placenta accreta Taiwanese Journal of Obstetrics and Gynecology 2006 45 2 100 106 10.1016/S1028-4559(09)60205-9 2-s2.0-33745918644 17197348 · DOI
  17. [20]Baltajian K. Hecht J. L. Wenger J. B. Placental lesions of vascular insufficiency are associated with anti-angiogenic state in women with preeclampsia Hypertension in Pregnancy 2014 33 4 427 439 10.3109/10641955.2014.926914 2-s2.0-84911477945 25062083 · DOI
  18. [21]Maynard S. E. Min J. Y. Merchan J. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia The American Society for Clinical Investigation 2003 111 5 649 658 10.1172/JCI17189 12618519 PMC151901 · DOI · Paper page
  19. [22]McMahon K. Karumanchi S. A. Stillman I. E. Cummings P. Patton D. Easterling T. Does soluble fms-like tyrosine kinase-1 regulate placental invasion? Insight from the invasive placenta American Journal of Obstetrics and Gynecology 2014 210 68 e61 e64 10.1016/j.ajog.2013.08.032 2-s2.0-84890858486 23994221 · DOI
  20. [23]Shainker S. A. Dannheim K. Gerson K. D. Down-regulation of soluble fms-like tyrosine kinase 1 expression in invasive placentation Archives of Gynecology and Obstetrics 2017 296 2 257 262 10.1007/s00404-017-4432-7 2-s2.0-85021106663 28631072 · DOI
  21. [24]Unemori E. N. Erikson M. E. Rocco S. E. Relaxin stimulates expression of vascular endothelial growth factor in normal human endometrial cells in vitro and is associated with menometrorrhagia in women Human Reproduction 1999 14 3 800 806 10.1093/humrep/14.3.800 10221717 · DOI
  22. [25]Goh W. Yamamoto S. Y. Thompson K. S. Bryant-Greenwood G. D. Relaxin, its receptor (RXFP1), and insulin-like peptide 4 expression through gestation and in placenta accreta Reproductive Sciences 2013 20 8 968 980 10.1177/1933719112472735 2-s2.0-84880436880 23302396 PMC3713646 · DOI
  23. [26]Kim K. R. Jun S. Y. Kim J. Y. Ro J. Y. Implantation site intermediate trophoblasts in placenta cretas Modern Pathology 2004 17 12 1483 1490 10.1038/modpathol.3800210 2-s2.0-10344246561 15205687 · DOI
  24. [27]Stanek J. Drummond Z. Occult placenta accreta: the missing link in the diagnosis of abnormal placentation Pediatric and Developmental Pathology 2007 10 4 266 273 10.2350/06-10-0174.1 2-s2.0-34548577651 17638431 · DOI
  25. [28]Tseng J. J. Hsu S. L. Wen M. C. Ho E. S. C. Chou M. M. Expression of epidermal growth factor receptor and c-erbB-2 oncoprotein in trophoblast populations of placenta accreta American Journal of Obstetrics & Gynecology 2004 191 6 2106 2113 10.1016/j.ajog.2004.04.043 2-s2.0-10044299373 15592299 · DOI
  26. [29]Smith S. C. Baker P. N. Symonds E. M. Placental apoptosis in normal human pregnancy American Journal of Obstetrics & Gynecology 1997 177 1 57 65 10.1016/S0002-9378(97)70438-1 2-s2.0-0030803861 9240583 · DOI
  27. [30]Millar L. Streiner N. Webster L. Early placental insulin-like protein (INSL4 or EPIL) in placental and fetal membrane growth Biology of Reproduction 2005 73 4 695 702 10.1095/biolreprod.105.039859 2-s2.0-25144435824 15958731 PMC1382170 · DOI
  28. [31]Gu Y. Bian Y. Xu X. Downregulation of miR-29a/b/c in placenta accreta inhibits apoptosis of implantation site intermediate trophoblast cells by targeting MCL1 Placenta 2016 48 13 19 10.1016/j.placenta.2016.09.017 2-s2.0-84991233473 27871464 · DOI
  29. [32]Ernst L. M. Linn R. L. Minturn L. Miller E. S. Placental pathologic associations with morbidly adherent placenta potential insights into pathogenesis Paediatric pathology society 2017 20 p. 5 10.2350/16-03-1789-oa.1 28812469 · DOI
  30. [33]Jabrane-Ferrat N. Siewiera J. The up side of decidual natural killer cells: new developments in immunology of pregnancy Immunology 2014 141 4 490 497 10.1111/imm.12218 2-s2.0-84895809996 24256296 PMC3956423 · DOI
  31. [34]Laban M. Ibrahim E. A.-S. Elsafty M. S. E. Hassanin A. S. Placenta accreta is associated with decreased decidual natural killer (dNK) cells population: a comparative pilot study European Journal of Obstetrics & and Reproductive Biology 2014 181 284 288 10.1016/j.ejogrb.2014.08.015 2-s2.0-84907970683 25195203 · DOI
  32. [35]Kalluri R. Weinberg R. A. The basics of epithelial-mesenchymal transition The Journal of Clinical Investigation 2009 119 6 1420 1428 10.1172/JCI39104 2-s2.0-67650999875 19487818 PMC2689101 · DOI · Paper page
  33. [36]Duzyj C. M. Buhimschi I. A. Motawea H. The invasive phenotype of placenta accreta extravillous trophoblasts associates with loss of E-cadherin Placenta 2015 36 6 645 651 10.1016/j.placenta.2015.04.001 2-s2.0-84929653092 25904157 · DOI
  34. [37]Zhu J. Y. Pang Z. J. Yu Y. H. Regulation of trophoblast invasion: the role of matrix metalloproteinases Reviews in Obstetrics & Gynecology 2012 5 3-4 e137 e143 23483768 PMC3594863
  35. [38]Demir-Weusten A. Seval Y. Kaufmann P. Demir R. Yucel G. Huppertz B. Matrix metalloproteinases-2, −3 and −9 in human term placenta Acta Histochemica 2007 109 5 403 412 10.1016/j.acthis.2007.04.001 2-s2.0-34748857301 17559909 · DOI
  36. [39]Kocarslan S. Incebıyık A. Guldur M. E. Ekinci T. Ozardali H. I. What is the role of matrix metalloproteinase-2 in placenta percreta? Journal of Obstetrics and Gynaecology Research 2015 41 7 1018 1022 10.1111/jog.12667 2-s2.0-84984622187 25656855 · DOI
  37. [40]Y K. E. Lu J. H. Yang B. L. Involvement of matrix metalloproteinase-2, −9, and tissue inhibitors of metalloproteinase-1, 2 in occurrence of the accrete placenta Zhonghua Fu Chan Ke Za Zhi 2006 41 5 311 314 10.3760/j.issn:0529-567x.2006.05.007 16762185 · DOI
  38. [41]Chen Y. Zhang H. Han F. The depletion of MARVELD1 leads to murine placenta accreta via integrin β4-dependent trophoblast cell invasion Journal of Cellular Physiology 2018 233 2257 2269 10.1002/jcp.26591 28708243 · DOI
  39. [42]Wang S. Li Y. Han F. Identification and characterization of MARVELD1, a novel nuclear protein that is down-regulated in multiple cancers and silenced by DNA methylation Cancer Letters 2009 282 1 77 86 10.1016/j.canlet.2009.03.008 2-s2.0-67649408809 19364627 · DOI
  40. [43]Burton D. G. Krizhanovsky V. Physiological and pathological consequences of cellular senescence Cellular and Molecular Life Sciences 2014 71 22 4373 4386 10.1007/s00018-014-1691-3 2-s2.0-84925283137 25080110 PMC4207941 · DOI · Paper page
  41. [44]Geffen T. Gal H. Vainer I. Senescence and telomere homeostasis might be involved in placenta percreta—preliminary investigation Reproductive Sciences 2017 10.1177/1933719117737852 29108468 · DOI
  42. [46]Lin T.-M. Halbert S. P. Kiefer D. Spellacy W. N. Gall S. Characterization of four human pregnancy-associated plasma proteins American Journal of Obstetrics & Gynecology 1974 118 2 223 236 10.1016/0002-9378(74)90553-5 2-s2.0-0015991033 4129188 · DOI
  43. [47]Conover C. A. Key questions and answers about pregnancy-associated plasma protein-A Trends in Endocrinology and Metabolism 2012 23 5 242 249 10.1016/j.tem.2012.02.008 2-s2.0-84860377296 22463950 PMC3348390 · DOI
  44. [48]Entrez gene: PAPPA pregnancy-associated plasma protein A, pappalysin 1 February 2018, https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=ShowDetailView&TermToSearch=5069
  45. [49]Lawrence J. B. Bale L. K. Haddad T. C. Clarkson J. T. Conover C. A. Characterization and partial purification of the insulin-like growth factor (IGF)-dependent IGF binding protein-4-specific protease from human fibroblast conditioned media Growth Hormone & IGF Research 1999 9 1 25 34 10.1054/ghir.1998.0083 2-s2.0-0033081345 10207505 · DOI
  46. [50]Laursen L. S. Overgaard M. T. Soe R. Pregnancy-associated plasma protein-A (PAPP-A) cleaves insulin-like growth factor binding protein (IGFBP)-5 independent of IGF: implications for the mechanism of IGFBP-4 proteolysis by PAPP-A FEBS Letters 2001 504 1-2 36 40 10.1016/S0014-5793(01)02760-0 2-s2.0-0035943504 11522292 · DOI
  47. [51]Laursen L. S. Kjaer-Sorensen K. Andersen M. H. Oxvig C. Regulation of insulin-like growth factor (IGF) bioactivity by sequential proteolytic cleavage of IGF binding protein-4 and −5 Molecular Endocrinology 2007 21 5 1246 1257 10.1210/me.2006-0522 2-s2.0-34250880671 17312271 · DOI
  48. [52]Sun I. Y. Overgaard M. T. Oxvig C. Giudice L. C. Pregnancy-associated plasma protein A proteolytic activity is associated with the human placental trophoblast cell membrane The Journal of Clinical Endocrinology & Metabolism 2002 87 11 5235 5240 10.1210/jc.2002-020561 2-s2.0-0036845353 12414897 · DOI
  49. [53]Gagnon A. Wilson R. D. Audibert F. Obstetrical complications associated with abnormal maternal serum markers analytes Journal of Obstetrics and Gynaecology Canada 2008 30 10 918 932 10.1016/S1701-2163(16)32973-5 2-s2.0-59749090676 19038077 · DOI
  50. [54]Kilcoyne A. Shenoy-Bhangle A. S. Roberts D. J. Sisodia R. C. Gervais D. A. Leeca S. I. MRI of placenta accreta, placenta increta, and Placenta Percreta: Pearls and Pitfalls American Journal of Roentgenology 2017 208 1 214 221 10.2214/AJR.16.16281 2-s2.0-85007406111 27762597 · DOI
  51. [55]Christopher Baughman W. Corteville J. E. Shah R. R. Placenta accreta: spectrum of US and MR iumaging findings Radiographics 2008 28 7 1905 1916 10.1148/rg.287085060 2-s2.0-58149377750 19001647 · DOI · Paper page
  52. [56]Zelop C. Nadel A. Frigoletto F. D. Jr Pauker S. MacMillan M. Benacerraf B. R. Placenta accreta/percreta/increta: a cause of elevated maternal serum alpha-fetoprotein Obstetrics and Gynecology 1992 80 4 693 694 1383899
  53. [57]Thompson O. Ogbah C. Nnochiri A. Sumithran E. Spencer K. First trimester maternal serum biochemical markers of aneuploidy in pregnancies with abnormally invasive placentation BJOG: An International Journal of Obstetrics and Gynaecology 2015 122 10 1370 1376 10.1111/1471-0528.13298 2-s2.0-84940102981 25639820 · DOI
  54. [58]Lawrence J. B. Oxvig C. Overgaard M. T. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A Proceedings of the National Academy of Sciences of the United States of America 1999 96 6 3149 3153 10.1073/pnas.96.6.3149 2-s2.0-0032981399 10077652 PMC15910 · DOI · Paper page
  55. [59]Krantz D. Goetzl L. Simpson J. L. Association of extreme first-trimester free human chorionic gonadotropin-β, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes American Journal of Obstetrics & Gynecology 2004 191 4 1452 1458 10.1016/j.ajog.2004.05.068 2-s2.0-7044261025 15507982 · DOI
  56. [60]Dugoff L. Hobbins J. C. Malone F. D. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (The FASTER Trial) American Journal of Obstetrics & Gynecology 2004 191 4 1446 1451 10.1016/j.ajog.2004.06.052 2-s2.0-7044251939 15507981 · DOI
  57. [61]Ong C. Y. T. Liao A. W. Spencer K. Munim S. Nicolaides K. H. First trimester maternal serum free β human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications BJOG: An International Journal of Obstetrics & Gynaecology 2000 107 10 1265 1270 10.1111/j.1471-0528.2000.tb11618.x 2-s2.0-0033799683 11028579 · DOI
  58. [62]Smith G. C. S. Stenhouse E. J. Crossley J. A. Aitken D. A. Cameron A. D. Connor J. M. Early pregnancy levels of pregnancy-associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth The Journal of Clinical Endocrinology & Metabolism 2002 87 4 1762 1767 10.1210/jcem.87.4.8430 11932314 · DOI
  59. [63]Tul N. Tul N. Pušenjak S. Osredkar J. Spencer K. Novak-Antolič Ž. Predicting complications of pregnancy with first-trimester maternal serum free-βhCG, PAPP-A and inhibin-A Prenatal Diagnosis 2003 23 12 990 996 10.1002/pd.735 2-s2.0-0347478051 14663836 · DOI
  60. [64]She B.-Q. Chen S.-C. Lee F.-K. Cheong M.-L. Tsai M.-S. Low maternal levels of pregnancy- associated plasma protein-A during the first trimester are associated with subsequent preterm delivery with preterm premature rupture of membranes Taiwanese Journal of Obstetrics & Gynecology 2007 46 3 242 247 10.1016/S1028-4559(08)60027-3 2-s2.0-35348889706 17962103 · DOI
  61. [65]Barrett S. L. Bower C. Hadlow N. C. Use of the combined first-trimester screen result and low PAPP-A to predict risk of adverse fetal outcomes Prenatal Diagnosis 2008 28 1 28 35 10.1002/pd.1898 2-s2.0-39149097569 18186146 · DOI
  62. [66]Pihl K. Sorensen T. L. Norgaard-Pedersen B. First-trimester combined screening for Down syndrome: prediction of low birth weight, small for gestational age and pre-term delivery in a cohort of non-selected women Prenatal Diagnosis 2008 28 3 247 253 10.1002/pd.1946 2-s2.0-41149124864 18302310 · DOI
  63. [67]Spencer K. Cowans N. J. Molina F. Kagan K. O. Nicolaides K. H. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery Ultrasound in Obstetrics & Gynecology 2008 31 147 152 10.1002/uog.5163 2-s2.0-43249123064 17992705 · DOI
  64. [68]Lyell D. Faucett A. Baer R. Maternal serum markers, characteristics and morbidly adherent pla- centa in women with previa Journal of Perinatology 2015 35 8 570 574 10.1038/jp.2015.40 2-s2.0-84938289621 25927270 · DOI
  65. [69]Tomasi T. B. Structure and function of alpha-fetoprotein Annual Review of Medicine 1977 28 1 453 465 10.1146/annurev.me.28.020177.002321 67821 · DOI
  66. [70]Speroff L. Fritz M. A. The endocrinology of pregnancy Clinical Gynecologic Endocrinology and Infertility 2005 7th Philadelphia, PA, USA Lippincott Williams & Wilkins 259 315
  67. [71]Dugoff L. First- and second-trimester maternal serum markers for aneuploidy and adverse obstetric out- comes Obstetrics and Gynecology 2010 115 5 1052 1061 10.1097/AOG.0b013e3181da93da 2-s2.0-77951578160 20410782 · DOI
  68. [72]Mizejewski G. J. Physiology of alpha-fetoprotein as a biomarker for perinatal distress: relevance to adverse pregnancy outcome Experimental Biology and Medicine 2007 232 8 993 1004 10.3181/0612-mr-291 2-s2.0-34548433585 17720945 · DOI
  69. [73]Cole L. A. Biological functions of hCG and hCG-related molecules Reproductive Biology and Endocrinology 2010 8 1 p. 102 10.1186/1477-7827-8-102 2-s2.0-77955818331 20735820 PMC2936313 · DOI
  70. [74]Shi Q. Lei Z. Rao C. V. Lin J. Novel role of human chorionic gonadotropin in differentiation of human cytotro- phoblasts Endocrinology 1993 132 3 1387 1395 10.1210/endo.132.3.7679981 2-s2.0-0027522771 7679981 · DOI
  71. [75]Costa S. L. Proctor L. Dodd J. M. Screening for placental insufficiency in high-risk pregnancies: is earlier better? Placenta 2008 29 12 1034 1040 10.1016/j.placenta.2008.09.004 2-s2.0-56249113278 18930542 · DOI
  72. [76]Liu D. F. Dickerman L. H. Redline R. W. Pathologic findings in pregnancies with unexplained increases in midtrimester maternal serum human chorionic gonadotropin levels American Journal of Clinical Pathology 1999 111 2 209 215 10.1093/ajcp/111.2.209 9930142 · DOI
  73. [77]Chandra S. Scott H. Dodds L. Watts C. Blight C. Van Den Hof M. Unexplained elevated maternal serum α-fetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes American Journal of Obstetrics & Gynecology 2003 189 3 775 781 10.1067/S0002-9378(03)00769-5 2-s2.0-0141859791 14526312 · DOI
  74. [78]Hung T. H. Shau W. Y. Hsieh C. C. Chiu T. H. Hsu J. J. Hsieh T. T. Risk factors for placenta accreta Obstetrics & Gynecology 1999 93 4 545 550 10.1016/s0029-7844(98)00460-8 10214831 · DOI
  75. [79]Dreux S. Salomon L. J. Muller F. Second-trimester maternal serum markers and placenta accreta Prenatal Diagnosis 2012 32 10 1010 1012 10.1002/pd.3932 2-s2.0-84866972374 22729439 · DOI
  76. [80]Desai N. Krantz D. Roman A. Fleischer A. Boulis S. Rochelson B. Elevated first trimester PAPP-A is associated with increased risk of placenta accreta Prenatal Diagnosis 2014 34 2 159 162 10.1002/pd.4277 2-s2.0-84895070855 24226752 · DOI
  77. [81]Büke B. Akkaya H. Demir S. Relationship between first trimester aneuploidy screening test serum analytes and placenta accreta The Journal of Maternal-Fetal & Neonatal Medicine 2017 31 1 59 62 10.1080/14767058.2016.1275546 2-s2.0-85009812094 28027672 · DOI
  78. [82]Mizejewski G. J. Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants Experimental Biology and Medicine 2001 226 5 377 408 10.1177/153537020122600503 11393167 · DOI
  79. [83]Carter C. S. Becker J. B. Neuroendocrinology of sexual behaviour in the female Behavioural Endocrinology 2002 Cambridge, MA, USA MIT Press 88 89
  80. [84]Waller D. K. Lustig L. S. Smith A. H. Hook E. B. Alpha-fetoprotein: a biomarker for pregnancy outcome Epidemiology 1993 4 5 471 476 10.1097/00001648-199309000-00014 2-s2.0-0027184356 7691189 · DOI
  81. [85]Lo Y. M. Corbetta N. Chamberlain P. F. Presence of fetal DNA in maternal plasma and serum The Lancet 1997 350 9076 485 487 10.1016/S0140-6736(97)02174-0 2-s2.0-0342618532 9274585 · DOI · Paper page
  82. [86]Sekizawa A. Jimbo M. Saito H. Increased cell-free fetal DNA in plasma of two women with invasive placenta Clinical Chemistry 2002 48 2 353 354 11805017
  83. [87]Samuel A. Bonanno C. Oliphant A. Batey A. Wright J. D. Fraction of cell-free fetal DNA in the maternal serum as a predictor of abnormal placental invasion-a pilot study Prenatal Diagnosis 2013 33 11 1050 1053 10.1002/pd.4195 2-s2.0-84886596023 23836321 · DOI
  84. [88]Ng E. K. Tsui N. B. Lau T. K. mRNA of placental origin is readily detectable in maternal plasma Proceedings of the National Academy of Sciences of the United States of America 2003 100 8 4748 4753 10.1073/pnas.0637450100 2-s2.0-0037447089 12644709 PMC153627 · DOI
  85. [89]Tjoa M. L. Jani J. Lewi L. Peter I. Wataganara T. Johnson K. L. etal. Circulating cell- free fetal messenger RNA levels after fetoscopic interventions of complicated pregnancies American Journal of Obstetrics & Gynecology 2006 195 1 230 235 10.1016/j.ajog.2006.01.041 2-s2.0-33745281724 16626602 · DOI
  86. [90]Dennis Lo Y. M. Chiu R. W. Prenatal diagnosis: progress through plasma nucleic acids Nature Reviews Genetics 2007 8 1 71 77 10.1038/nrg1982 2-s2.0-33845799282 17146468 · DOI
  87. [91]Maron J. L. Bianchi D. W. Prenatal diagnosis using cell-free nucleic acids in maternal body fluids: a decade of progress American Journal of Medical Genetics Part C, Seminars in Medical Genetics 2007 145C 1 5 17 10.1002/ajmg.c.30115 2-s2.0-33947204657 17299735 · DOI
  88. [92]Zhou J. Li J. Yan P. Maternal plasma levels of cell-free β-HCG mRNA as a prenatal diagnostic indicator of placenta accrete Placenta 2014 35 9 691 695 10.1016/j.placenta.2014.07.007 2-s2.0-84906793873 25063251 · DOI
  89. [93]El Behery M. M. Etewa Rasha L. El Alfy Y. Cell-free placental mRNA in maternal plasma to predict placental invasion in patients with placenta accreta International Journal of Gynecology & Obstetrics 2010 109 1 30 33 10.1016/j.ijgo.2009.11.013 2-s2.0-77349105955 20070963 · DOI
  90. [94]Ersoy A. O. Oztas E. Ozler S. Can venous ProBNP levels predict placenta accreta? The Journal of Maternal-Fetal & Neonatal Medicine 2016 29 24 4020 4024 10.3109/14767058.2016.1152576 2-s2.0-84961212879 26864469 · DOI
  91. [95]Oztas E. Ozler S. Caglar A. T. Yucel A. Analysis of first and second trimester maternal serum analytes for the prediction of morbidly adherent placenta requiring hysterectomy The Kaohsiung Journal of Medical Sciences 2016 32 579 585 10.1016/j.kjms.2016.08.011 2-s2.0-84995477569 27847101 PMC11916765 · DOI
  92. [96]Craven C. M. Chedwick L. R. Ward K. Placental basal plate formation is associated with fibrin deposition in decidual veins at sites of trophoblast cell invasion American Journal of Obstetrics & Gynecology 2002 186 2 291 296 10.1067/mob.2002.119717 2-s2.0-0036175737 11854653 · DOI
  93. [97]Vassiliadou N. Bulmer J. N. Characterization of tubal and decidual leukocyte populations in ectopic pregnancy: evidence that endometrial granulated lymphocytes are absent from the tubal implantation site Fertility and Sterility 1998 69 4 760 767 10.1016/S0015-0282(98)00005-3 2-s2.0-0031957730 9548170 · DOI
  94. [98]Qin L. Wang Y. L. Bai S. X. Temporal and spatial expression of integrins and their extracellular matrix ligands at the maternal-fetal interface in the rhesus monkey during pregnancy Biology of Reproduction 2003 69 2 563 571 10.1095/biolreprod.103.015198 2-s2.0-0037962068 12700193 · DOI
  95. [99]Kupferminc M. J. Tamura R. K. Wigton T. R. Glassenberg R. Socol M. L. Placenta accreta is associated with elevated maternal serum alpha-fetoprotein Obstetrics and Gynecology 1993 82 2 266 269 7687756

Cited by

Sorted by citations

Authors
Bartels, H. C., Postle, J. D., Downey, P., & Brennan, D. J.
Affiliations
  • National Maternity Hospital (IE)
  • University College Dublin (IE)
Corresponding author
Brennan, Donal J.
ORCID
Venue
Disease Markers
Publisher
Wiley
Published
2018-07-03
Volume
2018
Pages
1-11
ISSN
  • 0278-0240 (ISSN-L)
  • 1875-8630
DOI
10.1155/2018/1507674
PMC
PMC6051104
OpenAlex
W2810464718
Cited by
233
References
3
Citations by year
2026: 11 · 2025: 20 · 2024: 51 · 2023: 49 · 2022: 35 · 2021: 33 · 2020: 26 · 2019: 4 · 2018: 2
FWCI
3.11
Type
journal article
Language
en
Open access
Licence
Locations
  • Disease Markers (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Lenus, The Irish Health Repository (Dr Steevens Hospital Library) (submittedVersion, cc-by-nc-nd)
Topics
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Maternal and fetal healthcare
  • Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy and preeclampsia studies
  • Life Sciences › Immunology and Microbiology › Immunology › Reproductive System and Pregnancy
Keywords
placenta accreta spectrum, placenta accreta, placenta increta, placenta percreta, invasive placentation, maternal morbidity, histopathology, angiogenesis, cell proliferation, inflammation, serum biomarkers, human chorionic gonadotropin, PAPP-A, alpha-fetoprotein, disease stratification
MeSH terms
Female, Fetal Proteins, Gonadotropins, Humans, Placenta Accreta, Pregnancy, Pregnancy-Associated Plasma Protein-A, Biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review